New insights in the pathophysiology of chronic intermittent hypoxia-induced NASH: The role of gut-liver axis impairment

Thorax

Volumn 70, Issue 8, 2015, Pages 713-715

  Aron Wisnewsky, Judith ^a,b,c   Pepin, Jean Louis ^d,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Sorbonne Universités   (France)

^d UNIV GRENOBLE ALPES   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LIPOPOLYSACCHARIDE; PREBIOTIC AGENT; ADIPONECTIN;

CHRONIC INTERMITTENT HYPOXIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; EDITORIAL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPOGENESIS; LIPOTOXICITY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; BIOSYNTHESIS; FEMALE; LIVER; LIVER CELL; MALE; METABOLISM; PATHOLOGY;

ADIPONECTIN; FEMALE; HEPATOCYTES; HUMANS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; SLEEP APNEA, OBSTRUCTIVE;

EID: 84940783849     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207212     Document Type: Editorial

References (39)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332:1519-23.
2. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114:842-5.
3. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatol Baltim Md 2010; 52:774-88.
4. Lévy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34:243-60.
5. Savransky V, Reinke C, Jun J., et al. Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice. Exp Physiol 2009; 94:228-39.
6. Savransky V, Nanayakkara A, Vivero A., et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatol Baltim Md 2007; 45:1007-13.
7. Savransky V, Bevans S, Nanayakkara A., et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007; 293:G871-7.
8. Aron-Wisnewsky J, Minville C, Tordjman J., et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56:225-33.
9. Minville C, Hilleret MN, Tamisier R, et al. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea. Chest 2014; 145:525-33.
10. Musso G, Cassader M, Olivetti C., et al. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013; 14:417-31.
11. Polotsky VY, Patil SP, Savransky V, et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009; 179:228-34.
12. Corey KE, Misdraji J, Zheng H., et al. The absence of obstructive sleep apnea may protect against non-alcoholic fatty liver in patients undergoing bariatric surgery. PLoS ONE 2013; 8:e62504.
13. Schwimmer JB, Deutsch R, Kahen T., et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118:1388-93.
14. Molleston JP, Schwimmer JB, Yates K.P., et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164:707-13.e3.
15. Della Corte C, Vajro P, Socha P., et al. Pediatric non-alcoholic fatty liver disease: recent advances. Clin Res Hepatol Gastroenterol 2014; 38:419-22.
16. Patton HM, Sirlin C, Behling C., et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006; 43:413-27.
17. Nobili V, Cutrera R, Liccardo D., et al. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med 2014; 189:66-76.
18. Sundaram SS, Sokol RJ, Capocelli K.E., et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr 2014; 164:699-706.e1.
19. Tasali E, Ip MSM. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008; 5:207-17.
20. Vgontzas AN, Papanicolaou DA, Bixler E.O., et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85:1151-8.
21. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS ONE 2010; 5:e12065.
22. Trzepizur W, Le Vaillant M, Meslier N, et al. Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia. Chest 2013; 143:1584-9.
23. Li J, Thorne LN, Punjabi N.M., et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97:698-706.
24. Jun J, Savransky V, Nanayakkara A., et al. Intermittent hypoxia has organ-specific effects on oxidative stress. Am J Physiol Regul Integr Comp Physiol 2008; 295:R1274-81.
25. Paschetta E, Belci P, Alisi A., et al. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm 2015; 2015:815721.
26. Kheirandish-Gozal L, Peris E, Wang Y., et al. Lipopolysaccharide-binding protein plasma levels in children: effects of obstructive sleep apnea and obesity. J Clin Endocrinol Metab 2014; 99:656-63.
27. Lepper PM, Kleber ME, Grammer T.B., et al. Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease-results from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). Atherosclerosis 2011; 219:291-7.
28. Aron-Wisnewsky J, Gaborit B, Dutour A., et al. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19:338-48.
29. Bäckhed F, Ding H, Wang T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101:15718-23.
30. Amar J, Chabo C, Waget A., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3:559-72.
31. Cani PD, Amar J, Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-72.
32. Cani PD, Bibiloni R, Knauf C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57:1470-81.
33. Cani PD, Lecourt E, Dewulf E.M., et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90:1236-43.
34. Moreno-Indias I, Torres M, Montserrat J.M., et al. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J 2015; 45:1055-65.
35. Ye D, Li FYL, Lam KSL, et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. GUT 2012; 61:1058-67.
36. Poggi M, Bastelica D, Gual P., et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007; 50:1267-76.
37. Saberi M, Woods NB, de Luca C, et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009; 10:419-29.
38. Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010; 2010:pii: 192543.
39. Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatol Baltim Md 2003; 37:1043-55.